NeoGenomics (NEO) Stock Price, News & Analysis

NeoGenomics, Inc. (NASDAQ: NEO) is a cancer diagnostics company that focuses on oncology genetics testing and related information services. Classified within the testing laboratories industry and the professional, scientific, and technical services sector, the company concentrates on diagnostic and predictive testing that supports precision medicine in oncology.

According to the company’s public disclosures, NeoGenomics provides oncology diagnostic solutions that enable precision medicine and specializes in cancer genetics testing and information services. It offers one of the most comprehensive oncology-focused testing menus across the cancer continuum and serves oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms. These testing and information services are used to help diagnose and treat cancer and to support research and clinical development in oncology.

Business focus and services

NeoGenomics describes itself as a premier cancer diagnostics company with a broad oncology-centric test menu. Based on the available information, its activities include cancer diagnostic testing and consultative services, cancer genetics testing, and oncology-focused information services. The company’s offerings are used in clinical cancer testing, interpretation and consultative support for healthcare providers, and in clinical trials and research settings.

The company states that it operates a network of CAP-accredited and CLIA-certified laboratories that provide full-service sample processing and analysis services throughout the United States, along with a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. These laboratories support a range of oncology tests, including cancer genetics testing and other oncology diagnostics that can inform therapy selection, recurrence monitoring, and other aspects of cancer care.

Oncology testing capabilities

NeoGenomics highlights that it offers one of the most comprehensive oncology-focused testing menus across the cancer continuum. The company’s public communications emphasize capabilities in areas such as cancer genetics testing, molecular and next-generation sequencing (NGS) testing, and other oncology diagnostic and predictive tests. NeoGenomics has referenced next-generation sequencing assays and comprehensive genomic profiling in myeloid malignancies, as well as liquid biopsy-based assays and molecular residual disease (MRD) testing platforms used in research and clinical settings.

NeoGenomics has described specific assay platforms in its news releases, including the RaDaR family of assays for molecular residual disease detection and recurrence monitoring, and a Neo Comprehensive Myeloid panel for comprehensive genomic profiling in myeloid malignancies. The company has also referenced NEO | PanTracer LBx, a liquid biopsy precision oncology pan–solid tumor comprehensive genomic profiling assay. These examples illustrate the company’s focus on advanced molecular oncology testing and the use of circulating tumor DNA (ctDNA) and other genomic approaches in cancer diagnostics and research.

Customers and end markets

In its public descriptions, NeoGenomics states that it serves oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms. For healthcare providers, its oncology diagnostics and cancer genetics tests support diagnosis, prognosis, therapy selection, and recurrence monitoring. For pharmaceutical and biotechnology companies, NeoGenomics provides oncology testing and information services that can support clinical trials, drug development, and research collaborations, including MRD-focused studies and comprehensive genomic profiling in both hematologic and solid tumor malignancies.

The company has also emphasized its role in the community setting, noting that a large share of cancer care is delivered outside major academic centers. NeoGenomics’ management commentary highlights a focus on being a cancer testing partner to pathologists and oncologists in community practices, with an oncology-centric test menu designed to bring advanced cancer testing approaches to these settings.

Geographic footprint and laboratories

NeoGenomics is headquartered in Fort Myers, Florida, as indicated in its news releases and SEC filings. The company trades on The Nasdaq Stock Market LLC under the ticker symbol NEO, with its common stock registered pursuant to Section 12(b) of the Securities Exchange Act of 1934.

The company reports that it operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services across the United States. In addition, NeoGenomics operates a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. This footprint supports both U.S. and international oncology testing and research activities, including clinical cancer testing and clinical trials work.

Role in oncology diagnostics and research

NeoGenomics’ public communications describe a sustained emphasis on precision oncology, molecular diagnostics, and integration of cancer genetics testing into both clinical practice and research. The company has highlighted research and presentations at major medical meetings, including the San Antonio Breast Cancer Symposium, the American Society of Hematology Annual Meeting, the International Society of Liquid Biopsy Annual Congress, and the European Society for Medical Oncology Congress. These activities have focused on topics such as molecular residual disease detection using RaDaR assays, comprehensive genomic profiling in myeloid malignancies, and liquid biopsy-based genomic profiling across solid tumors.

Through these programs, NeoGenomics positions its assays and testing platforms as tools that can refine diagnosis, support prognosis, guide therapy selection, and inform recurrence monitoring in various cancer types. The company has also referenced studies that integrate its molecular results with clinical data from health information exchanges, underscoring the information services component of its business.

Regulatory and reporting context

NeoGenomics, Inc. is incorporated in Nevada and files periodic and current reports with the U.S. Securities and Exchange Commission (SEC) under Commission File Number 001-35756. Recent Form 8-K filings have covered quarterly financial results and board and executive changes. These filings confirm the company’s status as a Nasdaq-listed issuer and provide additional detail on its financial condition, governance, and operational updates.

In its financial communications, the company has discussed revenue growth driven by clinical test volumes and has highlighted the contribution of next-generation sequencing testing to its clinical revenue mix. It also reports on operating expenses, research and development spending, and the use of non-GAAP financial measures such as Adjusted EBITDA and Adjusted Gross Profit Margin, as described in its earnings releases furnished to the SEC.

Testing laboratories industry context

Within the testing laboratories industry, NeoGenomics is focused specifically on oncology diagnostics and cancer genetics testing. Its activities span clinical cancer testing, interpretation and consultative services, and oncology data and information services used by healthcare providers and pharmaceutical companies. The company’s emphasis on precision medicine, molecular residual disease testing, and comprehensive genomic profiling reflects a focus on advanced molecular techniques within the broader professional, scientific, and technical services sector.